Neurotech International Ltd (ASX: NTI) has made substantial strides in FY2024 with its NTI164 cannabinoid drug therapy, meeting key clinical trial endpoints for several paediatric neurological ...
Neurotech International Ltd. has received ethics approval to begin a pharmacokinetic study of its NTI164 drug in healthy adults, an important step for regulatory compliance in both the U.S. and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback